Abstract 995P
Background
Our real-world study aimed to assess the current treatment landscape of aHCC in Ontario, Canada.
Methods
This retrospective cohort study used provincial-level databases from Ontario, Canada to identify patients diagnosed with aHCC between April 2010 and March 2019 with follow-up data available until March 2020. De novo stage IV disease and/or receipt of first line (1L) systemic therapy (ST) was used to establish an aHCC diagnosis. Baseline characteristics, treatment patterns, clinical outcomes, health care resource utilization and costs (in 2020 Canadian dollars) were determined.
Results
A total of 7,322 patients were identified using HCC diagnosis codes, of which 802 met the aHCC diagnosis criteria (82% male, median age 66 years). More than half (N=427) received 1L STs (98% sorafenib; <2% lenvatinib), a quarter (N=195) were untreated, and 9% (N=72) were given locoregional therapy without use of ST. Only 4% (N=19) of 1L treated patients were given a 2L treatment. The median time from diagnosis to 1L ST initiation was 2.3 months and median time on 1L ST was 2.4 months. Median overall survival (mOS) from diagnosis was 9.0 months (95% confidence interval [CI]: 7.8-10.3) and 2.7 months (95% CI: 2.3-3.3) for the treated and untreated cohorts, respectively. The mean total cost per 1L treated patient was $49,640, with oral medications as the main cost driver followed by inpatient hospitalizations.
Conclusions
Our study confirmed guarded prognosis of aHCC despite treatments with sorafenib, in keeping with mOS observed in clinical trials. Low uptake of 1L ST and subsequent uptake of 2L underscores high attrition rates likely related to the frailty of aHCC patients and lack of adequate ST options. Future studies will inform whether immunotherapy-based treatments in the latest years will improve ST uptake, attrition rates and health outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
HOPE Research Centre.
Funding
AstraZeneca Canada Inc.
Disclosure
D. Bosse: Financial Interests, Personal, Financially compensated role: Ipsen, AstraZeneca, Bayer, Pfizer, Bristol-Meyers Squibb, Amgen, Merck, Knight Therapeutics, Eisai. Y. Kim, J. Tieu, S.Z. Wang: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca. C. Shephard: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks or ownership: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
1009P - Network meta-analysis of first-line systemic therapies for advanced hepatocellular carcinoma: A comparison of objective response rates
Presenter: Gagandeep Kaur
Session: Poster session 18
1010P - A parametric network meta-analysis of first-line systemic therapies for advanced hepatocellular carcinoma related to overall survival
Presenter: Akanksha Sharma
Session: Poster session 18
1011P - A prospective study of TACE combined with lenvatinib plus sintilimab for HCC with portal vein tumor thrombus
Presenter: Xiaoyan Ding
Session: Poster session 18
1012P - First-in-human study of ABSK-011, a novel, highly selective fibroblast growth factor receptor (FGFR) 4 inhibitor for treating advanced hepatocellular carcinoma (HCC) with FGF19 overexpression
Presenter: Ann-Lii Cheng
Session: Poster session 18
1013TiP - Refinement and validation of a comprehensive clinical diagnostic model (GAMAD) for early detection of hepatocellular carcinoma: A multicenter, prospective study protocol
Presenter: Tian Yang
Session: Poster session 18
1014TiP - Efficacy and safety of recombinant human adenovirus type 5 injection combined with transhepatic arterial embolization sequential thermal ablation for medium-and high-risk recurrent liver cancer: a prospective, open-label, randomized controlled study
Presenter: Jianjun Li
Session: Poster session 18
1015TiP - A Prospective, phase II clinical study of tislelizumab monotherapy or in combination with lenvatinib for neoadjuvant treatment of resectable hepatocellular carcinoma
Presenter: Tianqiang Song
Session: Poster session 18